Table 1.
Clinical and pathologic characteristics of patients with triple‐negative breast cancer stratified by gene mutation
| Characteristic | Without HR mutation (n = 79) | BRCA mutation (n = 13) | Non‐BRCA HR mutation (n = 14) | Other mutation (n = 14) | P value |
|---|---|---|---|---|---|
| Age (mean ± SD) | 53.2 ± 11.9 | 51.7 ± 8.9 | 52.0 ± 9.9 | 56.9 ± 10.3 | .589 |
| T | |||||
| T1 | 38 | 6 | 3 | 5 | .433 |
| T2 | 36 | 7 | 10 | 7 | |
| T3‐4 | 5 | 0 | 1 | 2 | |
| N | |||||
| N0 | 41 | 10 | 6 | 12 | .324 |
| N1 | 20 | 2 | 4 | 1 | |
| N2 | 6 | 0 | 2 | 1 | |
| N3 | 12 | 1 | 2 | 0 | |
| Grade | |||||
| 1 | 3 | 2 | 0 | 2 | .746 |
| 2 | 21 | 3 | 5 | 3 | |
| 3 | 49 | 7 | 8 | 8 | |
| Undetermined | 6 | 1 | 1 | 1 | |
| TP53 mutation | |||||
| Wild type | 29 | 0 | 2 | 7 | .011 |
| Mutation | 50 | 13 | 12 | 7 | |
| Family history | |||||
| All cancer | 33 | 9 | 3 | 5 | .085 |
| Breast/ovarian | 15 | 7 | 0 | 2 | .004 |
| Adjuvant chemotherapy | |||||
| No | 11 | 0 | 1 | 3 | .335 |
| Yes | 68 | 13 | 13 | 11 | |
| Anthracycline | 22 | 8 | 7 | 5 | |
| Taxane | 2 | 0 | 1 | 0 | |
| Combination | 43 | 5 | 5 | 3 | |
| Others | 1 | 0 | 0 | 3 | |
Abbreviations: Adjuvant chemotherapy: anthracycline alone; taxane, taxane‐containing chemotherapy (taxane + anthracycline allowed).
HR, homologous recombination.